[May 24, 2012] Relatively Low Forward P/E Ratio Detected in Shares of Endo Pharmaceuticals in the Pharmaceuticals Industry (ENDP, WCRX, CBRX, TEVA, AZN) Tweet May 24, 2012 (SmarTrend(R) News Watch via COMTEX) -- Below are the three companies in the Pharmaceuticals industry with the lowest forward price to earnings (P/E) ratios. Forward P/E uses estimated earnings to compare relative value among companies in the same industry. Generally, the lower the forward P/E, the more undervalued a company is believed to be.Endo Pharmaceuticals ranks lowest with a a forward P/E ratio of 5.71. Warner Chilcott is next with a a forward P/E ratio of 5.75. Columbia Laboratories ranks third lowest with a a forward P/E ratio of 6.30. Teva Pharmaceutical Industries follows with a a forward P/E ratio of 6.46, and AstraZeneca rounds out the bottom five with a a forward P/E ratio of 6.63. SmarTrend recommended that its subscribers protect gains by selling shares of AstraZeneca on February 15th, 2012 by issuing a Downtrend alert when the shares were trading at $45.43. Since that call, shares of AstraZeneca have fallen 9.6%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time. Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup [ Back To TMCnet.com's Homepage ]